
Registration is now open for our free expert-led webinar on streamlined evidence strategies for biosimilar approval, with a special focus on analytics, PK design and immunogenicity.
Join Conscio Group and leading experts from Medicines for Europe on December 10, 2025, at 2:00 PM CET (expected duration up to 80 minutes) for a focused webinar on how to design biosimilar evidence packages that are both streamlined and regulator-ready.
As regulatory expectations evolve, high-quality analytical similarity data, smart PK study design and robust immunogenicity assessment are becoming central to biosimilar approval strategies. This webinar will explore how to make these elements work together in practice – without unnecessary clinical trial burden.
Program highlights:
- Streamlined Biosimilar Development – Regulatory Evolution Backed by Science and Founded in Analytics
Speaker: Mina Grguri, Biosimilar Policy & Science Officer, Medicines for Europe - Integrating Immunogenicity Testing of Biosimilars into PK Study Design: Practical and Analytical Aspects
Speaker: Eliška Kohelová, Deputy Head of Biologics Department, Conscio Group - Opening & market insights
Host: Stephan Holl, CEO, Conscio Group
Take this opportunity to learn from policy, scientific and operational perspectives, and to discuss your questions directly with the speakers during the live Q&A.
Register here to secure your spot. Participation is free!
Want to explore what we discussed in the previous part of this webinar series? Watch the recording of our previous session:
From Analytical Similarity to Clinical Data – Webinar Recording
Additional News
11 September 2025
Meet us at CPHI 2025
This October, the global pharmaceutical community will gather in Frankfurt for CPHI 2025. Quinta-Analytica as a member of Conscio Group will be there too – visit us in the Contract Manufacturing Hall 5.1, Stand F1.
8 September 2025
Quinta-Analytica successfully passed two onsite FDA inspections
In the first half of 2025, Quinta-Analytica underwent two onsite inspections by the U.S. Food and Drug Administration (FDA).
21 July 2025
Boosting Bioanalytical Power for our clients
New ICP-MS Expands Our Capabilities




